WEDNESDAY, Oct. 13 (HealthDay News) -- Reboxetine is likely ineffective for the treatment of major depressive disorder and associated with harmful adverse events, according to a study published online Oct. 12 in BMJ.
WEDNESDAY, Oct. 13 (HealthDay News) -- Reboxetine is likely ineffective for the treatment of major depressive disorder and associated with harmful adverse events, according to a study published online Oct. 12 in BMJ.